{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.9","upperLimit":"18.5","value":"9.02"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Progression-free survival was calculated as the time between the enrollment to the first documentation of progressive disease or death from any cause during study, whichever occurs earlier using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Progressive Disease required increase of 25% from lowest response value in the serum M-component (absolute increase must be ≥ 0.5 g/dL) and/or urine M-component (absolute increase must be ≥ 200 mg/24 h).","dispersionType":"80% Confidence Interval","groups":[{"description":"Durvalumab 1500 mg IV + Daratumumab 16 mg/kg IV + Pomalidomide 4 mg/day Oral + Dexamethasone 40 mg Oral (20 mg for \\> 75 Years Old) administered within a 28-day cycle for a maximum of 22 cycles","id":"OG000","title":"PD3 Arm"}],"paramType":"MEDIAN","populationDescription":"All participants who received at least 1 dose of the study medications. Pre-specified for data to be collected only in the PD3 arm.","reportingStatus":"POSTED","timeFrame":"From enrollment to first documentation of progressive disease or death from any cause during study, whichever occurs earlier (up to approximately 66 months)","title":"Kaplan-Meier Estimate of Progression-Free Survival (PFS) - PD3 Arm","type":"SECONDARY","unitOfMeasure":"Months"}